{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:54:34Z","timestamp":1791057274913,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:19:04Z","timestamp":1789139944000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changing Patterns of Causes of Death in Patients With Multiple Myeloma During the Modern Therapeutic Era"],"prefix":"10.1016","author":[{"given":"Abel","family":"Rosado-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-4146","authenticated-orcid":false,"given":"Esther","family":"Ortega-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"C\u00e1rdenas-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Fe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Verdugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-7978","authenticated-orcid":false,"given":"Roc\u00edo","family":"Gavira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rossi-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"L\u00f3pez-Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-1891","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.09.004_bib0001","unstructured":"National Cancer Institute. SEER cancer stat facts: multiple myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed: January 28, 2025."},{"issue":"9","key":"10.1016\/j.clml.2026.09.004_bib0002","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.09.004_bib0003","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study","volume":"23","author":"Chang-Chan","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.004_bib0004","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2026.09.004_bib0005","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","article-title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","volume":"108","author":"McCurdy","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.004_bib0006","unstructured":"American Cancer Society. Survival rates for acute myeloid leukemia (AML). https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/detection-diagnosis-staging\/. Accessed January 28, 2025."},{"issue":"5","key":"10.1016\/j.clml.2026.09.004_bib0007","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clml.2026.09.004_bib0008","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.09.004_bib0009","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2026.09.004_bib0010","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2026.09.004_bib0011","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"issue":"10272","key":"10.1016\/j.clml.2026.09.004_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"10192","key":"10.1016\/j.clml.2026.09.004_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2026.09.004_bib0014","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cancers17050793","article-title":"Evolution of survival in patients with multiple myeloma over two decades: a real-world experience from a medium-level hospital","volume":"17","author":"Ortega-Vida","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2026.09.004_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.09.004_bib0016","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clml.2026.09.004_bib0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"GBD 2019 Cancer Collaborators. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups, 2010\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.004_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-018-0068-5","article-title":"A systematic classification of death causes in multiple myeloma","volume":"8","author":"Mai","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.09.004_bib0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.09.004_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ijc.32232","article-title":"Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013","volume":"146","author":"Casta\u00f1eda-Avila","year":"2020","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.clml.2026.09.004_bib0021","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2026.09.004_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.20192","article-title":"Temporal patterns in US population-based patient survival among adults treated with chemotherapy and\/or immunotherapy for multiple myeloma, 2000-2020","volume":"207","author":"Dores","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.004_bib0023","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.18324","article-title":"Predictors of early mortality in multiple myeloma: results from the Australian and New Zealand myeloma and related diseases registry (MRDR)","volume":"198","author":"McQuilten","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.12.023","article-title":"Trends in early mortality from multiple myeloma: a population-based analysis","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1186\/s12889-025-22240-2","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"25","author":"Diao","year":"2025","journal-title":"BMC Public Health"},{"issue":"12","key":"10.1016\/j.clml.2026.09.004_bib0026","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1080\/03007995.2016.1226166","article-title":"A retrospective analysis to examine factors associated with mortality in medicare beneficiaries newly diagnosed with multiple myeloma","volume":"32","author":"Yusuf","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"20","key":"10.1016\/j.clml.2026.09.004_bib0027","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/cncr.32357","article-title":"Characteristics of long-term survivors with multiple myeloma: a national cancer data base analysis","volume":"125","author":"Hsieh","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2026.09.004_bib0028","article-title":"Prevalence and mortality-related factors of multiple myeloma in Taiwan","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.clml.2026.09.004_bib0029","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.3390\/cancers16193364","article-title":"Gender-specific prognostic impact of treosulfan levels in high-dose chemotherapy for multiple myeloma","volume":"16","author":"Heini","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2026.09.004_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000478265","article-title":"Gender-specific aspects in patients with multiple myeloma undergoing autologous stem cell transplantation: a single-center experience","volume":"93","author":"Posch","year":"2017","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.clml.2026.09.004_bib0031","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1158\/1055-9965.EPI-11-0157","article-title":"Gender disparities in the tumor genetics and clinical outcome of Multiple myeloma","volume":"20","author":"Boyd","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clml.2026.09.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221086755","article-title":"Cardiovascular-specific mortality among multiple myeloma patients: a population-based study","volume":"13","author":"Yin","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.004_bib0033","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs Bortezomib and Carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.clml.2026.09.004_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.09.004_bib0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.09.004_bib0036","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.clml.2026.09.004_bib0037","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2026.09.004_bib0038","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy \u2013 incidence and risks. A review from the European Myeloma Network (EMN) and the Italian Society of Arterial Hypertension (SIIA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.004_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1078725","article-title":"Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"John","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:38:41Z","timestamp":1791056321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S2152265026032908"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing Patterns of Causes of Death in Patients With Multiple Myeloma During the Modern Therapeutic Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}